Regorafenib 160 mgd n 379 Placebo n 194 Eligibility n 573 Patients with HCC Progression on sorafenib ChildPugh A liver function RESORCE A Phase III Trial of SecondLine Regorafenib for HCC ID: 719814
Download Presentation The PPT/PDF document "Bruix J et al. Lancet 2017;389(10064):..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
